Temporary blood–brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma

Dréan, Antonin; Lemaire, Nolwenn; Bouchoux, Guillaume; Goldwirt, Lauriane; Canney, Michael; Goli, Larissa; Bouzidi, A.; Schmitt, Charlotte; Guehennec, Jeremy; Verreault, Maïté; Sanson, Marc; Delattre, Jean‐Yves; Mokhtari, Karima; Sottilini, Frédéric; Carpentier, Alexandre; Idbaïh, Ahmed

doi:10.1007/s11060-019-03204-0

Cited by 62 publications

(38 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BBBD with LIPU has been shown to enhance the delivery of a wide variety of agents into the brain in preclinical models. Chemotherapeutic drugs used in current neurooncological protocols such as doxorubicin, 65 temozolomide, 6 irinotecan, 6 carboplatin, 19 BCNU, 39 cytarabine, 75 or methotrexate 48 have been delivered in significant amounts after US-induced BBBD. Larger molecular weight molecules, such as monoclonal antibodies (trastuzumab 33 ), as well as cells (neuronal stem cells, 8 natural killer [NK] cells 1 ) have also been significantly delivered to rodent healthy brain parenchyma and metastases in the brain after BBB permeabilization.…”

Section: Us-induced Bbbd and Preclinical Tumor Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives

Canney

Bouchoux

Puget

et al. 2020

Neurosurgical Focus

Self Cite

View full text Add to dashboard Cite

Pediatric brain tumors are the most common solid tumor and the first cause of cancer death in childhood, adolescence, and young adulthood. Current treatments are far from optimal in most of these tumors and the prognosis remains dismal for many of them. One of the main causes of the failure of current medical treatments is in part due to the existence of the blood-brain barrier (BBB), which limits drug delivery to tumors. Opening of the BBB with low-intensity pulsed ultrasound (LIPU) has emerged during the last 2 decades as a promising technique for enhancing drug delivery to the brain. In preclinical models, enhanced delivery of a wide range of therapeutic agents, from low-molecular-weight drugs, to antibodies and immune cells, has been observed as well as tumor control and increased survival. This technique has recently entered clinical trials with extracranial and intracranial devices. The safety and feasibility of this technique has furthermore been shown in patients treated monthly for recurrent glioblastoma receiving carboplatin chemotherapy. In this review, the characteristics of the BBB in the most common pediatric brain tumors are reviewed. Then, principles and mechanisms of BBB disruption with ultrasound (US) are summarized and described at the histological and biological levels. Lastly, preclinical studies that have used US-induced BBB opening in tumor models, recent clinical trials, and the potential use of this technology in pediatrics are provided.

show abstract

Section: Us-induced Bbbd and Preclinical Tumor Modelsmentioning

confidence: 99%

“…Recently, significantly increased survival with a trend for tumor growth control was observed in U87 and patient-derived GBM cell-line models in mice treated with carboplatin and BBBD with an unfocused US device. 19…”

Section: Us-induced Bbbd and Preclinical Tumor Modelsmentioning

confidence: 99%

Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives

Canney

Bouchoux

Puget

et al. 2020

Neurosurgical Focus

Self Cite

View full text Add to dashboard Cite

show abstract

“…BBB disruption is characterized by non-uniform permeability dependent on tumor type and size and an unselective influx of low and high molecular weight into the brain. The clinical benefit of BBB disruption has not been established for the treatment of less sensitive tumors such as gliomas, but BBB disruption seems to increase survival in patients [ 62 , 63 ]. The delivery of chemotherapeutic agents into the brain may be improved through BBB disruption and across the Ommaya intraventricular reservoir [ 64 , 65 , 66 ].…”

Section: Aptamers In Neuro-oncologymentioning

confidence: 99%

Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology

Amero

Khatua

Rodríguez-Aguayo

et al. 2020

Cancers

View full text Add to dashboard Cite

A relatively new paradigm in cancer therapeutics is the use of cancer cell–specific aptamers, both as therapeutic agents and for targeted delivery of anticancer drugs. After the first therapeutic aptamer was described nearly 25 years ago, and the subsequent first aptamer drug approved, many efforts have been made to translate preclinical research into clinical oncology settings. Studies of aptamer-based technology have unveiled the vast potential of aptamers in therapeutic and diagnostic applications. Among pediatric solid cancers, brain tumors are the leading cause of death. Although a few aptamer-related translational studies have been performed in adult glioblastoma, the use of aptamers in pediatric neuro-oncology remains unexplored. This review will discuss the biology of aptamers, including mechanisms of targeting cell surface proteins, various modifications of aptamer structure to enhance therapeutic efficacy, the current state and challenges of aptamer use in neuro-oncology, and the potential therapeutic role of aptamers in pediatric brain tumors.

show abstract

“…This device (named SonoCloud R ) is composed of an implantable, unfocused single-element ultrasound transducer based on a 10-mm flat piezoceramic disk powered by an external generator 10 . After being tested on primates for toxicity and safety through MRI, PET, electroencephalography (EEG), somatosensory evoked potential (SSEP) monitoring, behavioral scales, and histopathological analysis [34], SonoCloud R has been used to disrupt the BBB and deliver high concentrations of carboplatin in mouse [35] and primate models [34]. The same system has also been used in a clinical trial to successfully release carboplatin in tumor areas of GBM patients [36].…”

Section: Mr Compatible Lifus Systemsmentioning

confidence: 99%

Magnetic Resonance Methods for Focused Ultrasound-Induced Blood-Brain Barrier Opening

et al. 2020

View full text Add to dashboard Cite

Since its discovery in 2001, the interest in the low-intensity focused ultrasound (FUS)-mediated blood-brain barrier (BBB) disruption to deliver genes and drugs to brain tissue has increased steadily. Increasingly sophisticated sonication protocols and dedicated hardware are being developed to efficiently and safely permeabilize the BBB, and novel magnetic resonance (MR)-based technologies have been designed to guide FUS-induced BBB opening protocols. MR imaging (MRI) allows not only to more precisely target brain regions and evaluate the outcome of sonication in terms of enhanced BBB permeability but also to control the effects of ultrasound on brain structure and function. This review summarizes the state of the art in current MRI hardware and methods used in BBB opening protocols both in pre-clinical and clinical settings.

show abstract

Temporary blood–brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma

Cited by 62 publications

References 24 publications

Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives

Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives

Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology

Magnetic Resonance Methods for Focused Ultrasound-Induced Blood-Brain Barrier Opening

Contact Info

Product

Resources

About